REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

Status unconfirmed · Phase 2

Conditions studied: HIV/AIDS

In brief

The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load \& increase changes in WBC white blood cell counts in the adult Remune dose vs the low dose Remune placebo groups. Additional objectives include changes in CD4+ \& CD8+ T cell counts along with increased HIV immunity.

Key facts

Study ID

NCT02291809

Run by

Immune Response BioPharma, Inc.

People needed

26

Starts

2017-11-01

Expected to finish

2019-11-01

Last updated by the study team

2016-02-23

Who can join

Age: 0 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children clinically diagnosed with HIV that are 3 months of age to the age 16 years old
• Subjects on any approved FDA antiviral medication except triple cocktail HAART drugs

You may not qualify if…

• Truvada
• Triple cocktail HAART drugs
• Healthy subjects

Where it is running

• Clinical Site TBA — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.